Cargando…

Predictive Efficacy of Low Burden EGFR Mutation Detected by Next-Generation Sequencing on Response to EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Carcinoma

Direct sequencing remains the most widely used method for the detection of epidermal growth factor receptor (EGFR) mutations in lung cancer; however, its relatively low sensitivity limits its clinical use. The objective of this study was to investigate the sensitivity of detecting an epidermal growt...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Hye Sook, Sung, Jae Sook, Yang, Song-Ju, Kwon, Nak-Jung, Jin, LiHua, Kim, Seung Tae, Park, Kyong Hwa, Shin, Sang Won, Kim, Han Kyeom, Kang, Jin-Hyoung, Kim, Jeong-Oh, Park, Jae Yong, Choi, Jin Eun, Yoon, HyoungKyu, Park, Chan Kwon, Yang, Kap-Seok, Seo, Jeong-Sun, Kim, Yeul Hong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3869671/ https://www.ncbi.nlm.nih.gov/pubmed/24376508 http://dx.doi.org/10.1371/journal.pone.0081975

Ejemplares similares

EGFR endocytosis is a novel therapeutic target in lung cancer with wild-type EGFR
por: Jo, Ukhyun, et al.
Publicado: (2014)

Clathrin‐mediated EGFR endocytosis as a potential therapeutic strategy for overcoming primary resistance of EGFR TKI in wild‐type EGFR non‐small cell lung cancer
por: Kim, Boyeon, et al.
Publicado: (2020)

KIF5B-RET Fusion gene may coincide oncogenic mutations of EGFR or KRAS gene in lung adenocarcinomas
por: Kim, Jeong-Oh, et al.
Publicado: (2015)

Amelioration of Hypercholesterolemia by an EGFR Tyrosine Kinase Inhibitor in Mice with Liver-Specific Knockout of Mig-6
por: Lee, Jun Choul, et al.
Publicado: (2014)

An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations
por: Park, Keunchil, et al.
Publicado: (2021)

Quantification of epidermal growth factor receptor (EGFR) mutation may be a predictor of EGFR‐tyrosine kinase inhibitor treatment response
por: Park, Ha Young, et al.
Publicado: (2016)

Role of IGF-Binding Protein 3 in the Resistance of EGFR Mutant Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitors
por: Choi, Yun Jung, et al.
Publicado: (2013)

EGFR Mutation Status in Lung Adenocarcinoma-Associated Malignant Pleural Effusion and Efficacy of EGFR Tyrosine Kinase Inhibitors
por: Yang, Jiyoul, et al.
Publicado: (2018)

Detection of somatic variants and EGFR mutations in cell-free DNA from non-small cell lung cancer patients by ultra-deep sequencing using the ion ampliseq cancer hotspot panel and droplet digital polymerase chain reaction
por: Sung, Jae Sook, et al.
Publicado: (2017)

Correction: Role of IGF-Binding Protein 3 in the Resistance of EGFR Mutant Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitors
por: Choi, Yun Jung, et al.
Publicado: (2019)

Changes in PD-L1 expression according to tumor infiltrating lymphocytes of acquired EGFR-TKI resistant EGFR-mutant non-small-cell lung cancer
por: Kim, Tae-Jung, et al.
Publicado: (2017)

PD‐L1 expression in ROS1‐rearranged non‐small cell lung cancer: A study using simultaneous genotypic screening of EGFR, ALK, and ROS1
por: Lee, Jongmin, et al.
Publicado: (2018)

Inhibiting EGFR/HER-2 ameliorates neuroinflammatory responses and the early stage of tau pathology through DYRK1A
por: Kim, Jieun, et al.
Publicado: (2022)

EGFR-Tyrosine Kinase Inhibitors Induced Activation of the Autocrine CXCL10/CXCR3 Pathway through Crosstalk between the Tumor and the Microenvironment in EGFR-Mutant Lung Cancer
por: Hong, Sook-hee, et al.
Publicado: (2022)

Clinical Characteristics and Continued Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Administration in EGFR-mutated Non-Small Cell Lung Cancer with Skeletal Metastasis
por: Hong, Sook-Hee, et al.
Publicado: (2016)

EGFR Gene Amplification and Protein Expression in Invasive Ductal Carcinoma of the Breast
por: Hwangbo, Won, et al.
Publicado: (2013)

Predictive Factors for Switched EGFR-TKI Retreatment in Patients with EGFR-Mutant Non-Small Cell Lung Cancer
por: Kwon, Byoung Soo, et al.
Publicado: (2017)

Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer
por: Ji, Wonjun, et al.
Publicado: (2013)

Evaluation of Two EGFR Mutation Tests on Tumor and Plasma from Patients with Non-Small Cell Lung Cancer
por: Kim, Jeong-Oh, et al.
Publicado: (2020)

A Highly Sensitive Next-Generation Sequencing-Based Genotyping Platform for EGFR Mutations in Plasma from Non-Small Cell Lung Cancer Patients
por: Shin, Jung-Young, et al.
Publicado: (2020)

Discovery and Evaluation of Polymorphisms in the AKT2 and AKT3 Promoter Regions for Risk of Korean Lung Cancer
por: Sung, Jae Sook, et al.
Publicado: (2012)

Chronic Obstructive Pulmonary Disease-Related Non-Small-Cell Lung Cancer Exhibits a Low Prevalence of EGFR and ALK Driver Mutations
por: Lim, Jeong Uk, et al.
Publicado: (2015)

The prognostic value of CT radiomic features for patients with pulmonary adenocarcinoma treated with EGFR tyrosine kinase inhibitors
por: Kim, Hyungjin, et al.
Publicado: (2017)

Targeting HSF1 as a Therapeutic Strategy for Multiple Mechanisms of EGFR Inhibitor Resistance in EGFR Mutant Non-Small-Cell Lung Cancer
por: Lee, Sangah, et al.
Publicado: (2021)

Tumor-specific delivery of therapeutic siRNAs by anti-EGFR immunonanoparticles
por: Kim, Jung Seok, et al.
Publicado: (2018)

Contribution of p53 in sensitivity to EGFR tyrosine kinase inhibitors in non-small cell lung cancer
por: Jung, Sangyong, et al.
Publicado: (2021)

Inhibition of choroidal neovascularization by homoisoflavanone, a new angiogenesis inhibitor
por: Kim, Jeong Hun, et al.
Publicado: (2008)

Lapatinib, a Dual EGFR and HER2 Tyrosine Kinase Inhibitor, Downregulates Thymidylate Synthase by Inhibiting the Nuclear Translocation of EGFR and HER2
por: Kim, Hwang-Phill, et al.
Publicado: (2009)

Osteosarcomatous Differentiation in Rebiopsy Specimens of Pulmonary Adenocarcinoma with EGFR-TKI Resistance
por: Ahn, Hyein, et al.
Publicado: (2018)

EGFR is a potential dual molecular target for cancer and Alzheimer’s disease
por: Choi, Hee-Jeong, et al.
Publicado: (2023)

An anti-EGFR × cotinine bispecific antibody complexed with cotinine-conjugated duocarmycin inhibits growth of EGFR-positive cancer cells with KRAS mutations
por: Jin, Junyeong, et al.
Publicado: (2018)

Cellular plasticity and immune microenvironment of malignant pleural effusion are associated with EGFR-TKI resistance in non–small-cell lung carcinoma
por: Jeong, Hyoung-oh, et al.
Publicado: (2022)

Feasibility of re‐biopsy and EGFR mutation analysis in patients with non‐small cell lung cancer
por: Kim, Tae‐Ok, et al.
Publicado: (2018)

The Clinical Significance of RAS, PIK3CA, and PTEN Mutations in Non-Small Cell Lung Cancer Using Cell-Free DNA
por: Chang, Won Jin, et al.
Publicado: (2020)

Oncogenic fusion of BCAR4 activates EGFR signaling and is sensitive to dual inhibition of EGFR/HER2
por: Bae, Kieun, et al.
Publicado: (2022)

The efficacy of EGFR-tyrosine kinase inhibitor in non-small cell lung cancer patients with synchronous brain metastasis: a real-world study
por: Choi, Jin-Hyuk, et al.
Publicado: (2022)

Targeted sequencing identifies genetic alterations that confer primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium)
por: Lim, Sun Min, et al.
Publicado: (2016)

Mechanisms of resistance to EGFR tyrosine kinase inhibitors
por: Huang, Lihua, et al.
Publicado: (2015)

Complete mitochondrial genome of the crinoid Poliometra prolixa (Crinoidea: Comatulida: Antedonidae)
por: Kwon, Hayoung, et al.
Publicado: (2023)

Selective Immune Modulating Activities of Viscum album and Its Components; A Possibility of Therapeutics on Skin Rash Induced by EGFR Inhibitors
por: Choi, Hye Jin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_v1f2ctddr826iul1e8t67fqtv5